Onyx Pharmaceuticals Inc.'s investors were fired up Monday over top-line Phase IIb data that showed patients with relapsed-refractory multiple myeloma receiving carfilzomib as a single agent had an overall response rate of 24 percent, with a median duration of response of 7.4 months and no new or unexpected toxicities. (BioWorld Today) Read More
